CoChat

Bone-Fracture-Targeted Dasatinib-Oligoaspartic Acid Conjugate Potently Accelerates Fracture Repair

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

Approximately 6.3 million bone fractures occur annually in the United States, resulting in considerable morbidity, deterioration in quality of life, loss of productivity and wages, and sometimes death (e.g., hip fractures). Although anabolic and antiresorptive agents have been introduced for treatment of osteoporosis, no systemically administered drug has been developed to accelerate the fracture-healing process. To address this need, we have undertaken to target a bone anabolic agent selectively to fracture surfaces in order to concentrate the drug's healing power directly on the fracture site. We report here that conjugation of dasatinib to a bone fracture-homing oligopeptide via a releasable linker reduces fractured femur healing times in mice by ∼60% without causing overt off-target toxicity or remodeling of nontraumatized bones. Thus, achievement of healthy bone density, normal bone volume, and healthy bone mechanical properties at the fracture site is realized after only 3-4 weeks in dasatinib-targeted mice, but it requires ∼8 weeks in PBS-treated controls. We conclude that targeting of dasatinib to bone fracture surfaces can significantly accelerate the healing process at dasatinib concentrations that are known to be safe in oncological applications.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.bioconjchem.8b00660

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 58 references

Research works printed but not linked: 3

  1. 10.2174/1874467211205020153 · doi:10.2174/1874467211205020153 · Paper page
  2. Peruzzi B., 2012, Protein Kinases, 357
  3. Dittmer D. K., 1993, Can. Fam. Physician Med. Fam. Can., 39, 1428

Cited by

See all 25

Metadata

Authors
Wang, M., Park, S., Nam, Y., Nielsen, J., Low, S. A., Srinivasarao, M., & Low, P. S.
Affiliations
Purdue University West Lafayette (US)
Corresponding author
Low, Philip S.
Venue
Bioconjugate Chemistry
Published
2018-10-31
Volume
29
Issue
11
Pages
3800-3809
ISSN
  • 1043-1802 (ISSN-L)
  • 1520-4812
OpenAlex
W2899187179
Cited by
24
References
58
Citations by year
2025: 1 · 2024: 4 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 4 · 2018: 1
FWCI
2.93
Type
journal article
Language
en
Open access
closed
Locations
  • Bioconjugate Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone fractures and treatments
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
dasatinib, fracture healing, targeted drug delivery, femoral fracture, bone remodeling, bone mechanical properties, hip fracture
MeSH terms
Dasatinib, Animals, Aspartic Acid, Cell Line, Female, Oligopeptides, Quality of Life, Bone Density, Drug Delivery Systems, Fracture Healing, Protein Kinase Inhibitors, Fractures, Bone, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bone-Fracture-Targeted Dasatinib-Oligoaspartic Acid Conjugate Potently Accelerates Fracture Repair. https://app.cochat.ai/papers/10.1021/acs.bioconjchem.8b00660
The paper
Wang, M., Park, S., Nam, Y., Nielsen, J., Low, S. A., Srinivasarao, M., & Low, P. S. (2018). Bone-Fracture-Targeted Dasatinib-Oligoaspartic Acid Conjugate Potently Accelerates Fracture Repair. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.8b00660

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.